EGFR and non-small cell lung carcinoma: In a Phase II clinical trial, 40 EGFR-TKI-advanced EGFR-mutant NSCLC patients were enrolled for chemo-immuno-anti-angiogenesis therapy, resulting in impressive mPFS (9.4 months), one-year OS (72.5%), and ORR (62.5%), with only 37.5% reporting irAEs [68].